Published in Gene Therapy Weekly, May 9th, 2002
Vein graft disease is characterized by neointimal thickening and the risk for thrombosis in the grafted vein. Vascular smooth muscle cells are the major constituents of neointimal hyperplasia, making them suitable targets for strategies designed to control proliferation following surgery. Because CNP inhibits vascular smooth muscle cells, investigators at Kyoto University Graduate School of Medicine in Japan believe it could be used in gene therapy to prevent vein graft disease while at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.